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INTRODUCTION 
 
Ribosomes play an important role in the molecular life of a cell, providing the basis for 
protein production thus allowing cells growth and proliferation. In growing cells the 
synthesis of new ribosomes is fundamental and the ribosome biogenesis is one of the 
most energetically active processes. To understand the extent of this process, it is 
sufficient to consider that in an eukaryotic cell ribosomal RNA (rRNA) accounts up to 
80% of total cellular nucleic acid (Lempiäinen and Shore 2009) and every second in a 
growing yeast cell 40 nascent ribosomes leave the nucleolus, the major site of ribosome 
production, for export into the cytoplasm (Harris and Levine 2005).  
The close relationship between ribosome biogenesis and cell growth and proliferation is 
emphasized by the fact that the biological mechanisms which control cell proliferation 
also control ribosome biogenesis.  This process in fact can be regulated by the products of 
the same genes that control cell cycle entry and cell cycle progression, as it will be 
explained later. These are the same genes that undergo mutations during the neoplastic 
transformation in order to promote a more rapid cell proliferation. For this reason, 
ribosome biogenesis process is frequently altered in cancer cells. 
In active proliferating cells any stress which interferes with the ribosome biogenesis 
process, e.g. the inhibition of rRNA synthesis, induces a cell response causing either a 
block in cell cycle progression or the death of the cell (Pardee 1989). 
These effects appear to be mediated by the tumor suppressor protein p53 whose levels 
increase in the cell following ribosome biogenesis inhibition. 
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THE P53 TUMOR SUPPRESSOR  
 
The p53 protein is considered one of the most important tumor suppressors because of its 
importance in preventing the growth and survival of potentially malignant cells.  
In the nucleus p53 works predominantly as a transcription factor that enhances the rate of 
transcription of several genes connected with cell proliferation. Many types of stress 
activate p53, including DNA damage, oncogene activation, hypoxia and nucleolar stress. 
Activation of p53 can induce different responses in the cells, including differentiation, 
senescence, DNA repair and the inhibition of angiogenesis, but the most relevant effect is 
the ability of p53 to induce cell cycle arrest and/or apoptotic cell death (Ryan et al. 2001). 
In this way p53 inhibits the proliferation of stressed cells either by causing the cycle 
arrest, which might be transient to allow damages repair before cell cycle progression, or 
by inducing apoptosis to eliminate the damaged cell. Both responses can prevent 
replication of cells undergoing neoplastic transformation and in this way inhibit tumor 
development. Because p53 plays a role in preventing tumor cell growth at several points 
during the transformation process, the loss of p53 function is one of the mutation most 
frequently observed in cancer cells and can be found in about 50% of tumors (Levine 
1997). 
 
From a structural point of view, the human p53 protein contains 393 amino acids and has 
been functionally divided into four domains. The N-terminus consists of a transcriptional 
activator domain which interacts with the transcription machinery and positively regulates 
gene expression. This domain also interacts with the p53 negative regulator MDM2 (Lin 
et al. 1995). The sequence-specific DNA-binding domain of p53 is localized between 
amino acid residues 102 and 292. It is a protease-resistant and independently folded 
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domain containing a Zn
2+
 ion that is required for its sequence specific DNA-binding 
activity (Cho et al. 1994). Amino acid residues 324–355 are required for the 
oligomerization of the protein, in fact p53 works as a tetramer. The C-terminal 26 amino 
acids form an open protease-sensitive domain, this domain regulates the ability of p53 to 
bind to specific DNA sequences at its central or core domain (Lee et al. 1995). 
 
 
Regulation of p53 
 
As p53 is such a potent inhibitor of proliferation, it must be tightly regulated. This control 
is achieved through several mechanisms, such as regulation of transcription and 
translation, but rapid response to cell stresses is mediated by post-transcriptional control 
that lead to stabilization and activation of p53 (Woods and Vousden 2001). 
One of the key regulators of p53 stability is the protein mouse double minute 2 (MDM2, 
HDM2 in humans). It is an E3 ubiquitin ligase that works targeting proteins for 
proteasome degradation. MDM2 ubiquitination of p53 occurs in the C-terminus of the 
protein. It has been discovered that p53 ubiquitination is also essential for its nuclear 
export to the cytoplasm because it allows the nuclear export sequence to reveal (Boyd et 
al. 2000). The critical role of MDM2 in p53 regulation has been shown by the observation 
that MDM2 gene deletion was lethal in mice with functional p53 during early 
embryogenesis, whereas simultaneous deletion of TP53 and MDM2 genes allowed the 
normal development. It means that in mice during development MDM2 is essential for 
negative regulation of p53 function (Jones et al. 1995). 
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As MDM2 is a transcriptional target of p53 it exists an auto-regulatory feedback loop in 
which increased p53 activity leads to increased expression of its own negative regulator 
(Harris and Levine 2005).  
Increased stability of p53 in response to cellular stresses involves the inhibition of MDM2 
function through several pathways. 
Furthermore, the regulation of p53 activity is obtained through a series of post-
translational modifications which involve its C-terminal domain thus affecting p53 DNA 
binding ability. The main modifications are phosphorylation (Meek 1999), sumoylation 
(Gostissa et al. 1999) and acetylation (Gu and Roeder 1997). As an example, in response 
to DNA damage different kinases are activated, e.g. ataxia-telangiectasia-mutated (ATM), 
ataxia and rad3 related (ATR), and phosphorylate p53 hindering MDM2 binding. 
During neoplastic transformation the stabilization of p53 in response to abnormal 
proliferation associated with oncogene activation (such as RAS or MYC overexpression) 
does not require phosphorylation of p53, but depends to a large extent on activation of the 
p14ARF protein, whose function is to bind and to inhibit MDM2 directly (Sherr and 
Weber 2000). 
 
 
p53 and cell cycle control 
 
To better understand how p53 controls cell cycle progression, a short description of cell 
cycle phases and regulation is necessary. 
The cell cycle consists of a specific sequence of events, finely regulated, that leads to cell 
growth and culminate with the production of two separate cells.  
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Briefly, the cell cycle is composed of two main stages: interphase and mitosis. During 
interphase, the cell grows in size and duplicate DNA through different stages: Gap1 (G1), 
Synthesis (S) and Gap2 (G2).  During the G1 the cell grows increasing its size and 
produce the elements necessary for the following stage, the S phase, in which the cell 
duplicate its DNA. After DNA synthesis during the G2 phase the cell continues to grow 
in order to produce the material needed for cell division. Mitosis is the stage in which the 
cell effectively generates two different daughter cells. Mitosis includes prophase, 
metaphase, anaphase and telophase. Cells in G1 can, if not committed to DNA 
replication, enter a resting state called G0. Cells in G0 account for the major part of the 
non-growing, non-proliferating cells in the human body (reviewed in Norbury and Nurse 
1992).  
 
 
 
 
Figure 1: Schematic representation of cell cycle phases in eukaryotic cells. 
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The transition from one phase to another occurs in an orderly way and is finely regulated 
by different cellular proteins. The key regulators of this process are the cyclin-dependent 
kinases (CDKs), a family of serine/threonine protein kinases that are activated at specific 
points of the cell cycle. CDK protein levels remain stable during the cell cycle, in contrast 
to their activating proteins, the cyclins. Binding to a Cyclin is necessary for the activation 
of CDKs (Pines 1995). Cyclin protein levels rise and fall during the cell cycle and they 
periodically activate CDKs (Evans et al. 1983).  
Thus, the cell enters and exits the cell cycle in association with production and activation 
of specific Cyclins. Generally to proceed to the following phase the previous Cyclin is 
degraded and another one has to be synthesized (Schafer 1998). 
Until now, nine CDKs have been identified and, of these, five are active during the cell 
cycle. Each CDK has one or more corresponding Cyclin and act in a precise step of the 
cell cycle (Vermeulen et al. 2003). When CDKs are active they phosphorylate target 
proteins resulting in changes that catalyze the process of cell division. The most studied 
target of CDKs is the Retinoblastoma protein (pRb). Hypo-phosphorylated pRb binds the 
E2F-1 transcription factor, inactivating it. During early G1, CDK4/6-Cyclin D complexes 
phosphorylate pRb leading to the release of E2F-1. This factor positively regulate the 
transcription of genes whose products are required for S phase progression, including 
Cyclin A and Cyclin E. pRb remains hyper-phosphorylated for the remainder of the cell 
cycle and CDK2-Cyclin E participates in maintaining this state (Buchkovich et al. 1989).  
CDKs activity can be inhibited by negative regulator proteins, called CDK inhibitors 
(CKI) which bind to CDKs alone or to the CDK-Cyclin complex and regulate their 
activity. Two distinct families of CDK inhibitors have been discovered: the INK4 family 
and the Cip/Kip family (Sherr and Roberts 1995). The INK4 family includes p15 
(INK4b), p16 (INK4a), p18 (INK4c), p19 (INK4d), which specifically inactivate G1 
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CDKs (Cdk4 and Cdk6). This CKI family forms stable complexes with the CDKs 
preventing the association with Cyclin D (Carnero and Hannon 1998). The second family 
of inhibitors, the Cip/Kip family, includes p21 (Waf1/Cip1), p27 (Cip2), p57 (Kip2). 
These inhibitors inactivate CDK-Cyclin complexes and are of primary importance in G1 
regulation (Polyak et al. 1994). The p21 family binds to Cyclins preventing pRb 
phosphorylation and inhibits its dissociation from E2F-1. They inhibit to a lesser extent, 
CDK1-Cyclin B complexes (Hengst and Reed 1998). p21 also inhibits DNA synthesis by 
binding to and inhibiting the proliferating cell nuclear antigen (PCNA) a subunit of DNA 
Polymerase δ which has a role in DNA replication and repair (Pan et al. 1995). 
To ensure a quality control on cell cycle progression and an orderly sequence of events 
there are some checkpoints. In response to DNA damage checkpoints arrest the cells in 
order to provide time to repair the problem. The two mains checkpoints are positioned 
before or after DNA duplication: the G1-S and the G2-M checkpoint. 
 
The tumor suppressor p53 exerts its control on cell cycle progression mainly acting on the 
transcription activation of the p21 gene (el-Deiry et al. 1993). As previously described, 
the induction of p21 expression results in CDKs inhibition and cell cycle arrest at the G1-
S checkpoint. The p21 protein in fact inhibits the phosphorylation of the pRB protein 
preventing E2F-1 release. 
The protein p53 may also play a role in the regulation of the G2-M checkpoint. DNA 
damage-dependent increase of p53 results in increased transcription of p21 and of 14-3-3 
σ. The 14-3-3 σ protein can bind to the Cyclin B and can actively exclude it from the 
nucleus (Hermeking et al. 1997).  
10 
 
Another transcriptional target of p53 is Gadd45 (growth arrest and DNA damage 
inducible gene) whose product mediates the dissociation of CDK1-Cyclin B1 complexes 
(Taylor and Stark 2001). 
 
 
p53 induction of apoptosis 
 
The first evidence that p53 induces apoptosis was given by Oren and co-workers who 
showed that the reintroduction of p53 into a p53-deficient myeloid leukemia cell line 
caused apoptosis (Yonish-Rouach et al. 1991). The main role of p53 induced apoptosis is 
to suppress tumorigenesis but it also contributes to chemotherapy induced cell death in 
human cancer. Consistent with this role the loss of p53 can be linked to chemotherapy 
resistance in certain type of tumors (Johnstone et al. 2002). 
In human cells apoptosis can be induced following two pathways. The extrinsic pathway 
involves a series of cell surface receptors which activate intracellular proteins. The 
intrinsic pathway involves the mitochondria which contain apoptogenic factors, such as 
cytochrome c, second mitochondria-derived activator of caspases (SMAC), apoptosis 
inducing factor (AIF) and endonuclease G. Both pathways lead to the activation of a class 
of specific proteases, the caspases. Once the caspases are activated the process of cellular 
death is irreversible.  
The p53 protein regulates the apoptotic pathway by modulating key control factors in the 
intrinsic pathway. 
The protein p53 can transcriptionally activate some proapoptotic genes of the Bcl-2 
family: BAX, PUMA, OXA and BID. These proteins effects increase the quantity of pro-
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apoptotic Bcl-2 proteins, thereby favoring the release of apoptogenic compounds from the 
mitochondria, leading to caspase activation and apoptosis (Fridman and Lowe 2003).  
There is evidence that p53 can also promote apoptosis through transcription independent 
mechanisms. Recently a small fraction of the p53 protein was shown to allow 
permeabilization of the outer mitochondrial membrane directly by forming inhibitory 
complexes with the protective Bcl-XL and Bcl-2 proteins, leading to the release of 
cytochrome c (Mihara et al. 2003). 
Another role for p53 in promoting apoptosis is due to changes induced in REDOX 
metabolism. This leads to an increase in reactive oxygen species (ROS) that, perhaps by 
interfering with mitochondrial function and integrity, contributes to cell death (Polyak et 
al. 1997).  
  
 
RIBOSOME BIOGENESIS 
 
The ribosome biogenesis process requires the coordinated action of all three nuclear RNA 
polymerases (Pol I, II and III). Pol I transcribes a single 47S rRNA precursor (pre-rRNA), 
which is subsequently processed into the mature 18S, 5.8S and 28S rRNA. Pol II 
transcribes the mRNA required in the cytoplasm for the synthesis of ribosomal proteins 
(RPs). Pol III synthesizes the 5S rRNA and other non-coding RNAs (van Riggelen et al.  
2010; Roeder and Rutter 1970; Weinmann and Roeder 1974). These components are 
assembled in the nucleolus to form the mature subunits that are exported to the cytoplasm 
where the ribosomes perform protein synthesis. 
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The nucleolus 
 
The nucleolus is the compartment of the interphase nucleus where the ribosome 
biogenesis takes place. The structure of the interphase nucleolus is organized around the 
genes of rDNA and is maintained by transcription and ribosome assembly. In the human 
genome rDNA is present as head-to-tail tandem repeated genes. During mitosis the 
nucleolus disassembles to reassemble after cell division and the rDNA localize on the 
short arm of the five acrocentric chromosomes 13, 14, 15, 21 and 22, in regions called 
“nucleolar organizer regions” NORs (Derenzini 2000) 
Observing the nucleolus by electron microscopy, it is possible to identify three major 
regions with different morphology:  
 The fibrillar center (FC) appears as a roundish clear area characterized by low 
electron opacity. Generally cells with a high rate of ribosome biogenesis possess 
numerous small FCs, as an example cycling cells. On the contrary, cells with 
greatly reduced metabolic and transcription activities, present small nucleoli with 
one large-sized FC such as in lymphocytes (Derenzini et al. 1990). 
 The dense fibrillar component (DFC) constitutes a rim intimately associated with 
the fibrillar centers composed of densely packed fibrils. (Derenzini 2000).  
 The granular component (GC) is mainly composed of granules of 15-20 nm in 
diameter surrounding the DFC. 
 
Figure 2: Electron microscope 
visualization of the nucleolus. Three 
fibrillar centers are present (*), with 
the closely associated dense fibrillar 
component (f). The granular 
component (g) is organized in cord-
like structures (Montanaro et al. 2008). 
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The localization of the ribosome biogenesis machineries has led to assign specific 
functions to different compartments of the nucleolus (Derenzini et al. 1990). 
Nascent transcripts appear at the junction between the FCs and DFC and accumulate in 
the DFC.  Processing of the 47S pre-rRNA starts at the site of transcription in the DFC 
(Cmarko et al. 2000) and continues during the intranucleolar migration of the rRNA 
towards the GC. The nucleolar proteins that participate in the early stages of rRNA 
processing, localize in the DFC, such as Fibrillarin and Nucleolin along with the U3 
snoRNAs, whereas proteins that are involved in intermediate or later stages of processing, 
such as Nucleophosmin (B23), have been localized to the GC (Biggiogera et al. 1989; 
Ginisty et al. 1998; Ochs et al. 1985; Gautier et al. 1994). 
Nucleoli can be stained rather selectively within cell nuclei with reactions based on the 
reduction of metallic ions, the most commonly used are silver nitrate and silver 
ammonium salts (Schwarzacher and Mosgoeller 2000). Some of the proteins located in 
the fibrillar components (Nucleolin, Nucleophosmin, UBF, the largest RNA polymerase I 
subunit) are selectively stained by the reaction with these metallic ions, therefore these 
proteins are called AgNOR proteins (Sirri et al. 2000). This procedure allows visualizing 
at the light microscopy the interphase NORs, in fact after the staining they appear as well-
defined black dots within the nucleolar body. These structures can be quantified by 
morphometric analysis and their size is proportional to the nucleolar transcriptional 
activity (Derenzini et al. 1998). AgNORs can be considered a simple method to obtain 
information on the ribosome biogenesis activity of the cell and can be applied to the study 
of nucleolar alterations in tumor cells (Montanaro et al. 2008).  
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RNA polymerase I and rRNA synthesis 
 
The process of assembling a ribosome subunit requires the initial transcription of rDNA 
genes by the specific RNA polymerase I. 
A human diploid cell has approximately 400 repeats of rDNA but only a subset of these 
(~50%) is transcribed at any given time.  
In mammals, each rDNA repeat is approximately 43 kb and is composed by intergenic 
spacers (IGS) of approximately 30 kb and a single transcribed region of approximately 13 
kb containing the 47S coding region. The gene promoters are contained in the IGS rRNA 
and their main regulatory elements are the core promoter and the upstream control 
element (reviewed by McStay and Grummt 2008). 
 
 
Figure 3: General organization of a rDNA gene and promoter (Goodfellow and 
Zomerdijk 2013). 
 
Specific transcription factors are necessary for accurate recruitment of Pol I and for the 
formation of pre-initiation complex (PIC) at the gene promoter. The main proteins 
involved in this process are selectivity factor 1 (SL1) and UBF. SL1 recognizes and binds 
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the core promoter element in the rDNA, it is essential for Pol I recruitment to the 
transcription start site and promotes a stable interaction between UBF and the rDNA 
promoter (Friedrich et al. 2005).  To achieve activated transcription, UBF must also be 
incorporated into the PIC where it interacts with SL1 at the rDNA promoter and with the 
PAF53 and PAF49/CAST Pol I subunits (Hanada et al. 1996; Panov et al. 2006). 
In mammalian cells, the Pol I complex exists as two distinct subpopulations: Pol Iα and 
Pol Iβ. Both forms are active and can catalyze the synthesis of RNA, but only Pol Iβ, 
which represents less than 10% of the total Pol I in a cell, can be incorporated into PICs 
and initiate transcription. This is due, at least in part, to the association of Pol Iβ with 
TIF1A which interacts with Pol I A43 subunit (Miller et al. 2001; Cavanaugh et al. 2002). 
Pol I must dissociate from the promoter-bound initiation factors in a process known as 
promoter escape. Promoter escape following transcription initiation coincides with the 
release of TIF1A from polymerase (Panov et al. 2006). 
Transcription elongation is highly efficient with about 100 Pol I complexes transcribing 
each active gene, at a rate of approximately 95 nucleotides per second (Dundr et al. 
2002).  
Several enzymatic complexes cooperate with PolI to optimize the rRNA transcription 
process. For example Topoisomerase IIα is a component of Pol Iβ in human cells and is 
necessary in order to remove topological changes in the rDNA (Panova et al. 2006). 
Furthermore, various DNA repair proteins have been found in Pol I complexes thus 
transcription-coupled DNA repair occurs at rDNA genes (Conconi et al. 2002). 
Transcription termination by Pol I is a multistep process involving specific DNA 
sequence elements and regulatory proteins. In mammals, transcription termination factor 
(TTF-I) binds to terminator elements downstream of the rRNA gene, causing polymerase 
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pausing. Dissociation of the paused transcription complex is then mediated by Pol I 
transcript release factor (PTRF) (Jansa and Grummt 1999). 
 
 
From rRNA to ribosome subunits 
 
The pre-rRNA 47S transcribed by the Pol I undergo chemical modifications to specific 
nucleotide cleavages to remove transcribed spacers, thus releasing the mature-size 18S 
28S and 5.8S rRNA species. 
 
 
 
 
 
 
 
 
 
Pre-rRNA processing begins on the 47S primary transcript by snipping both ends of the 
molecule at sites 01 and 02 in the 5’- and 3’-ETS segments, respectively, generating the 
45S pre-rRNA. The 45S precursor is matured following two major alternative pre-rRNA 
processing pathways that appear to differ not in the nature of the actual processing sites 
used but rather in the kinetics and order of cleavage. Both pathways produce three mature 
rRNA 18S, 5.8S and 28S as shown in fig. 4 (Mullineux and Lafontaine 2012). 
Figure 4: Pre-rRNA processing scheme in HeLa cells (Henras et al. 2008). 
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There is evidence that the first processing event occurs before the pre-rRNA transcript is 
completed (Lazdins et al. 1997). 
The pathways of pre-rRNA processing involve both endo- and exonucleases, many of this 
3’5’ exonucleases are contained in particles called ‘exosomes’ (Allmang et al. 1999). 
An important role in rRNA processing is exerted by small nuclear RNAs (snoRNAs) 
which are involved in different steps of the process: they can act as RNA chaperones to 
produce folding patterns recognized by the nucleases, they can be components of the 
ribonucleoprotein ribonucleases and the majority of them are guides for RNA 
modification (Borovjagin and Gerbi 1999). In the pre-rRNA the main modifications 
consist of 29-O-methylation of ribose groups and the conversion of uridine to 
pseudouridine (Olson et al. 2000).  
There is an important group of nucleolar proteins contained in the small nuclear 
ribonucleoprotein (snoRNPs). Although little is known about most of them, the snoRNP 
U3-associated protein Fibrillarin has been studied extensively and it has been shown to be 
essential for pre-rRNA processing, pre-rRNA methylation and ribosome assembly 
(Tollervey and Kiss 1997). 
Many nucleolar proteins are involved in pre-RNA processing, among them Nucleolin and 
Nucleophosmin (protein B23). Nucleolin primary function is to facilitate the early stages 
of pre-rRNA processing, possibly by first interacting with the 5’region of pre-rRNA and 
then recruiting processing components (Ginisty et al. 1998). Several activities of protein 
B23 have been identified in vitro, including nucleic acid and nuclear localization signal 
binding, stimulation of nuclear import, and ribonuclease and molecular chaperone 
activities (Szebeni and Olson 1999).  
The mature rRNAs are assembled in the nucleolus with the ribosomal proteins and with 
the 5S rRNA. The ribosomal proteins are synthetized in the cytoplasm and then imported 
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in the nucleus. The 5S-rRNA is synthetize in the nucleoplasm by the action of the Pol III 
and then is transported in the nucleolus. The 5S genes are present in multiple copies 
located outside the NORs and near the telomere of the long arm of chromosome 1 
(Srivastava and Schlessinger 1991). 
In mammals the mature ribosome is composed of two subunits: the small 40S ribosomal 
subunit, which contains one 18S rRNA and approximately 32 ribosomal proteins (RPS), 
and the large 60S subunit, which is composed of one of each 5S, 5.8S and 28S rRNA and 
approximately 47 ribosomal proteins (RPL).  
The subunits are assembled into the nucleolus and then exported into the cytoplasm to 
perform protein synthesis (van Riggelen et al. 2010). 
 
 
Ribosome biogenesis regulation  
 
Growing and proliferating cells need to maintain high rates of Pol I transcription to 
sustain the level of ribosomes required for protein synthesis. Conditions that influence 
cell growth and proliferation, such as growth factor, nutrients and energy availability can 
regulate Pol I transcription.   
The main mediator between these environmental conditions and ribosome biogenesis is 
mTORC1 (mammalian target of rapamycin complex 1) that contains the evolutionary 
conserved serine/threonine kinase mTOR and can control Pol I transcription via different 
pathways (Kusnadi et al. 2015). 
First, mTORC1 signaling activates TIF1A by increasing phosphorylation at serine 44, 
required for TIF1A activity, and decreasing phosphorylation at serine 199 (Mayer et al. 
2004).  Moreover, mTOR regulates UBF in an S6K1-dependent manner. Mitogen-
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induced activation of S6K1 phosphorylates UBF in its C-terminal region,  
phosphorylation required for the interaction between UBF and SL1 (Hannan et al. 2003).  
Another important regulator of ribosome biogenesis is the transcription factor MYC, 
which can be activated in response to growth factor stimuli. Elevated expression of MYC 
regulates Pol I transcription by two different mechanisms. First, it can act by stimulating 
the transcription of factors associated with Pol I, such as UBF, TIF1A and Pol I subunits   
(Poortinga et al. 2014). Secondly, MYC can activate PolI transcription in a double 
manner: by binding to the rDNA promoter region remodeling rDNA chromatin structure 
and by directly interacting with SL1 promoting the stabilization of the UBF/SL1 complex 
(Arabi et al. 2005; Grandori et al. 2005).  
In addition to these two major pathways for ribosome biogenesis regulations, there are 
other intracellular signaling ways that can modulate this process in response to external 
stimuli. One of these pathways leads to ERK (extracellular signal-regulated kinase) 
activation. It can phosphorylate TIF1A at serine 649 and serine 633 and UBF, thus 
promoting Pol I transcription (Zhao et al. 2003).  
Another factor involved in Pol I regulation is the serine/threonine kinase AKT, which 
upregulates rDNA transcription at multiple steps, including transcription initiation, 
elongation, and rRNA processing, through both mTORC1-dependent and independent 
mechanisms (Chan et al. 2011). 
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Figure 5: the complex pathway of ribosome biogenesis regulation. mTORC1 links the 
availability of growth factors, amino acids and glucose to rDNA transcription. MYC 
expression stimulates Pol I trough different mechanisms  (Kusnadi et al. 2015). 
 
The mechanisms which control cell proliferation also control ribosome biogenesis; this 
underlines the close relationship linking ribosome biogenesis to cell growth and 
proliferation.  This process in fact can be regulated by the products of the same genes that 
control cell cycle entry and cell cycle progression.  
 
Cyclin D and E can induce the phosphorylation of UBF, by Cdk4-Cyclin D1 and Cdk2-
Cyclin E complexes, thus enhancing the transcription of ribosome genes (Voit et al. 
1999). 
There is evidence that pRB, in addition to controlling the transition from G1 to S phase, 
also modulates ribosome biogenesis. Active, hypo-phosphorylated pRB inhibits rRNA 
synthesis by binding to UBF (Cavanaugh et al. 1995). Therefore, in cycling cells hyper-
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phosphorylation of pRB induces an increase of the rRNA transcription rate, along with an 
enlargement of the nucleolar size.  
The protein p53, in addition to its role in response to cellular stresses, directly influences 
ribosome biogenesis. Accumulation of the wild-type p53 inhibits Pol I transcription by 
binding to the selectivity factor SL1 and by hindering the formation of the UBF-SL1 
complex (Zhai and Comai 2000). The activity of p53 may also be activated by the tumor 
suppressor protein p14Arf, which also hinders the ribosome biogenesis by inhibiting UBF 
recruitment on the transcription complex and by lengthening rRNA processing 
(Bertwistle et al. 2004; Ayrault et al. 2006).  
Lastly, PTEN (phosphatase and tensin homolog deleted in chromosome 10), another 
important tumor suppressor which inhibits cell proliferation, also represses Pol I 
transcription by disrupting the SL1 complex ( Zhang et al. 2005). 
 
Ribosome Biogenesis alterations in cancer 
 
Human cancer cells are frequently characterized by nucleolar hypertrophy, characteristic 
that is often associated with an upregulated ribosome biogenesis process. Interestingly, 
several human cancers have been analyzed, using AgNOR staining, and nucleolar sizes 
appear to be very variable within both different histotypes and the same tumor sample. 
This can be explained by the fact that the nucleolar changes in tumors are closely related 
to the number and the rapidity of proliferating cells within the cancer tissue, kinetics 
parameters that are highly variable in human tumors ( Derenzini et al. 1998;  Derenzini et 
al. 2000).  
It is known that neoplastic transformation is characterized by mutations which activates 
oncogenes or inactivate tumor suppressor genes. As explained in the previous chapter, the 
22 
 
products of these genes regulate not only cell proliferation but also ribosome biogenesis. 
Therefore these neoplastic mutation might result in the enhancement of the ribosome 
biogenesis process (Montanaro et al. 2008). 
Among the tumor suppressor genes RB1 and TP53 are the most important, their 
inactivation is linked to the induction of genetic instability and a poor prognosis in cancer 
cells, but it is also responsible for the upregulation of ribosome biogenesis process 
(Cordon-Cardo 1995). It has been observed that in human tumors the degree of nucleolar 
hypertrophy was directly related to the severity of the pRB and p53 pathway alterations: 
cancers without change of pRB and p53 presented small nucleoli whereas cancers with 
RB1 loss and mutated TP53 showed hypertrophic nucleoli (Treré et al. 2004;  Derenzini 
et al. 2004).  
 
 
Figure 6: Histological sections of two human breast carcinomas, stained for the 
AgNOR proteins. Note the small size on the nucleoli in the case reported in a and the 
larger size of nucleoli in the case reported in b (Montanaro et al. 2008). 
 
 
Another oncogene which is frequently altered in cancer cells is c-MYC, its overexpression 
induces cell growth and proliferation but also stimulate rRNA transcription and ribosome 
production. 
a b 
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Also Cyclin D and E, which control the cell cycle progression, may be overexpressed or 
altered in human tumors and can directly activate ribosome biogenesis (Montanaro et al. 
2008). 
The ARF gene may be mutated or silenced in tumor cells (Sherr 2001); the loss of 
p14ARF expression may be responsible for the enhancement of ribosome biogenesis both 
directly and through the action on p53 stabilization.  
Also, the tumor suppressor PTEN is very frequently deleted or mutated in human cancers 
(Yin and Shen 2008), in which its repressive action on Pol I transcription may be lost. 
According to these data, the up-regulation of ribosome biogenesis in cancer cells appears 
to be as an adaptation of the nucleolus to the neoplastic transformed cell. In fact, in this 
way the cell guarantees the production of the constituents needed for the appropriate 
division (Derenzini et al. 2005). 
However, there is also evidence of an active role for nucleolus in cancer development. A 
series of human pathological conditions are linked to an increased risk of cancer onset, 
such, for example, tissues with chronic inflammation.  
Hepatitis B (HBV) and C (HCV) viruses, which are responsible for chronic liver disease, 
have also been shown to upregulate the activity of Pol I and III (Kao et al. 2004; Wang et 
al. 1998). Interestingly, the presence of abnormally enlarged hepatocyte nucleoli 
represents a strong risk factor in the development of hepatocellular carcinoma, mainly in 
HBV-related cirrhotic livers (Trerè et al. 2003). 
Moreover, a recent study shows that Interleukin-6 (IL6), which is produced in tissues 
with chronic inflammation, induced an rRNA transcription up-regulation with the 
consequent p53 degradation and activation of the epitelial-mesenchimal transition  
process (Brighenti et al. 2014).   
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Apart from the quantitative variation of the rate of ribosome synthesis, specific qualitative 
alterations in the process of ribosome biogenesis are responsible for a series of human 
diseases in which cancer incidence is very high (Narla and Ebert 2010) 
The Dyskeratosis congenita is a ribosomal disorder in which the molecular connections 
between the qualitative alterations of ribosome biogenesis and cancer have been better 
characterized. It is caused by mutations in the DKC1 gene whose product, dyskerin, is a 
nucleolar protein necessary for the site-specific conversion of uridine to pseudouridine 
presents in the rRNA molecules. The reduction in modified uridine residues in the 
ribosome might result in an impaired translation of specific mRNAs encoding for tumor 
suppressors such as p53 and/or p27, explaining the increased tumor susceptibility 
characteristic of this pathology (Bellodi et al. 2010; Bellodi et al. 2010). 
Another well-characterized ribosome biogenesis diseases is Diamond-Blackfan anemia, a 
group of inherited bone marrow failure disorders (Ellis and Lipton 2008). The 25% of 
patients are reported to carry a mutation in RPS19, but mutations in other RPs have been 
reported (Gazda et al. 2008; Campagnoli et al. 2008). In conjunction with chronic anemia 
and congenital abnormalities, Diamond–Blackfan anemia patients also have a 
predisposition to development of cancer (Deisenroth and Zhang 2010). 
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THE RIBOSOMAL PROTEINS-MDM2-P53 PATHWAY 
 
The synthesis of new rRNA is an integral process of ribosome biogenesis that needs to be 
continually monitored to ensure appropriate balance between rRNA synthesis and RPs 
availability (Lempiäinen and Shore 2009). 
Perturbations of many aspects of ribosome biogenesis contribute to ‘nucleolar stress’ 
which leads to the breakdown of nucleolar structure. Following nucleolar stress the RPs-
Mdm2-p53 response pathway is activated and p53 levels arise in the cell. As previously 
described, in fact, one of the primary mechanisms to induce p53 stability is through 
modifications in the MDM2-p53 interaction.  
HDM2 is characterized by an N-terminal domain which binds p53, a C-terminal domain 
which promotes p53 ubiquitination, and a central region which contains multiple sites for 
binding and regulation by different proteins, including pRb, ARF, p300 histone 
acetyltransferase and some ribosomal proteins (Zhang et al. 2003). 
Marechal and colleagues were the first to report RPs interaction with Mdm2, they 
described the RPL5 binding to Mdm2 in a 5S rRNA ribonucleoprotein complex, but at 
the time, the meaning of this interaction was unclear (Marechal et al., 1994). 
The interaction between ribosomal proteins and Mdm2 was deeply studied in the 
following years and the proteins RPL5, RPL11 and RPL23 were all reported to bind to 
Mdm2, inhibiting its E3 ubiquitin ligase function and promoting p53 accumulation (Y. 
Zhang et al. 2003; Bhat et al. 2004; Dai and Lu 2004). Subsequently, further RPs were 
described as Mdm2 binding partners: RPS7 (Chen et al. 2007), RPL26 (Ofir-Rosenfeld et 
al. 2008) and RPS3 (Yadavilli et al. 2009). 
In this scenario, perturbations to the synthesis of rRNA precursors can induce ribosome 
biogenesis disruption with the release of ribosomal proteins that, no longer utilized for 
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ribosome building, are free to bind to Mdm2 inhibiting its E3 ubiquitin ligase activity 
thus causing p53 accumulation in the cell.  
This has been repeatedly demonstrated using rRNA synthesis inhibitors. The most 
utilized compound which selectively impair rRNA synthesis is Actinomycin D (Act D), 
an anticancer antibiotic which at low doses (<10 nM) specifically inhibits the production 
of rRNA. Actinomycin D has a high affinity for deoxyguanine nucleotides and 
preferentially intercalates into the GC rich regions of rDNA to inhibit PolI-mediated 
transcription of nascent 47S rRNA (Perry and Kelley 1970). This interaction leads to 
nucleolar stress with consequent p53 stabilization. In addition to Act D, several chemical 
reagents have been found to trigger nucleolar stress by inhibiting rRNA processing or 
synthesis, such as 5-fluorouracil (5-FU) and mycophenolic acid (MPA) (Sun et al. 2008; 
Sun et al. 2007) 
Nucleolar disruption is not always a necessary condition to induce RPs-Mdm2 interaction 
and p53 stabilization. A study conducted in our laboratory showed that gene silencing of 
POLR1A, a component of Pol I, caused rRNA synthesis inhibition without inducing 
nucleolar disruption and could anyway stabilize p53 through the RPs-Mdm2 interaction 
(Donati et al. 2011). 
Recently, the research is addressing to the development of new anticancer molecules 
directly inhibiting RNA PolI I activity and able to activate p53 through the RP-Mdm2 
interaction. Among these, CX-5461 inhibits ribosome biogenesis by disrupting the SL-1 
rDNA complex. This drug was shown to induce p53-mediated death of Lymphoma cells 
via activation of the Rp-MDM2-p53 pathway in a mouse model of lymphoma with MYC 
overexpression (Eμ-Myc). CX-5461 was able to kill selectively transformed malignant 
cells sparing normal B cells. Thanks to this result the drug is used in clinical trials for the 
treatment of hematologic malignancies (Bywater et al. 2012). 
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The RPs-Mdm2 pathway seems to have relevance not only in the response to 
chemotherapy treatments but also in neoplastic transformation. In fact, it has been shown 
that stimulation of ribosome biogenesis results in a greater degradation of p53 due to the 
fact that the quantity of ribosomal proteins necessary for ribosome biogenesis is increased 
with the consequent reduction of the amount of RPs which inhibit MDM2.  Stimuli which 
increase rRNA synthesis, such as Insulin, Insulin-like growth factor 1, Interleukin-6 
downregulate the cell tumor suppressor potential by decreasing p53 levels (Donati et al. 
2011; Brighenti et al. 2014). 
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AIMS OF THE THESIS 
 
 
Many chemotherapeutic drugs actually used in cancer treatment hinder the process of 
ribosome biogenesis as a direct or indirect consequence of their action (Burger et al. 
2010). 
In the p53 wild-type cancers the ribosome biogenesis inhibiting drugs can contribute to 
the therapy effectiveness promoting p53 stabilization. Indeed, as a consequence of rRNA 
synthesis inhibition the ribosomal proteins, no longer utilized in the ribosomes building, 
bind to MDM2 and inhibit its E3-ubiquitin ligase activity therefore causing p53 
accumulation in the cell. Since a functional ribosome biogenesis process requires the 
stoichiometric production of rRNA and RPs (Donati et al. 2011), we hypothesized that in 
cancer cells characterized by different levels of rDNA transcription the ribosome 
biogenesis inhibition could lead to the release of a different amount of RPs which bind to 
and inactivate MDM2 causing differences in the level of p53 stabilization.  
The main purpose of this work was to assess the relationship between the cell ribosome 
biogenesis rate and the p53 stabilization level in wild-type p53 human cancers after 
treatments with rRNA synthesis-inhibiting drugs. We found that the inhibition of rRNA 
synthesis caused greater p53 stabilization in the cells characterized by an elevated 
ribosome biogenesis process compared with the cells in which this process was lower. 
We also found that according to the level of p53 stabilization these rRNA inhibitors may 
induce an arrest of cell cycle progression or the apoptotic cell death.  The induction of 
apoptosis occurred only in cells in which the ribosome biogenesis rate, evaluated before 
the drug exposure, was very high, differently from the cells characterized by a low 
ribosome biogenesis rate in which only a cell cycle arrest was induced.   
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Since these data demonstrated that the induction of apoptosis was due to a high degree of 
p53 stabilization, we finally investigated whether the combination of rRNA synthesis 
inhibitors with drugs which do not inhibits ribosome biogenesis, such as Hydroxyurea, 
could increase the effectiveness of the treatment by increasing p53 stabilization. 
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MATERIALS AND METHODS 
 
 
Cell cultures and chemical treatments 
Six p53 wild-type human cancer cell lines (HepG2, HCT116, U2OS, MCF7, LoVo and 
ZR-75-1) were obtained from the American Type Culture Collection. HCT116 p53 − / − 
cell line was a generous gift of Professor Bert Vogelstein. The cell lines were cultured in 
monolayer at 37°C in humidified atmosphere containing 5% of CO2. HepG2, HCT116 
and U2OS were grown in Dulbecco’s Modified Eagle Medium. MCF7 and ZR-75-1 cell 
lines were cultured in RMPI-1640 and LoVo in Ham’s F12 nutrient mixture. Human 
lymphocytes were recovered from healthy donors. Peripheral blood mononuclear cells 
(PBMCs) were isolated by density gradient centrifugation using Ficoll Histopaque-1077, 
according to manufacturer’s instructions. The cells were grown in RPMI-1640 medium. 
In order to obtain monocyte depletion PBMCs were cultured for 1 h at 37°C to allow 
monocyte adhesion and the lymphocytes suspended in the media were collected. 
Lymphocyte proliferation was obtained by adding 10 μg/mL of Phytohemoagglutinin 
(PHA) to the medium. All culture media were addicted with 10% Foetal Bovine Serum 
(FBS), 1% of penicillin and streptomycin, 1% of glutamine, and 0.5% of non-essential 
amino acids. All media and reagents were purchased from Sigma-Aldrich (Milan, Italy).  
Serum starvation was obtained by culturing cells in medium containing 0.2% Foetal 
Bovine Serum. 
Actinomycin D (Biovision, Mountain View, CA, USA) was used at the final 
concentration of 8 nM; Doxorubicin (Doxorubicin Hydrochloride Injection, USP, Pfizer, 
New York, USA) at 10 µM; 5-Fluorouracil (Fluorouracile, Teva Pharma Italia, Milan, 
Italy) was used at the dose of 20 µg/ml; Hydroxyurea (Sigma-Aldrich) was used at the 
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concentration of 3,4 mM; Nutlin-3 (Sigma-Aldrich) was used at 10 µM; CX-5461 
(Selleckchem, Huston, TX, USA) was used at 1 µM.  
 
Analysis of rRNA synthesis by 5-FU incorporation 
Analysis of nascent rRNA was performed on cells grown on coverslips by incorporation 
of 5-fluorouridin accordingly to the method described by Boisvert et al. 2000. Cells were 
incubated for 20 min in medium containing 2mM 5-fluorouridine (5-FU) (Sigma–
Aldrich) then washed in cold PBS and fixed in 2% paraformaldehyde and 1% Triton X-
100. Samples were incubated for 30 min in PBS with 1% bovine serum albumin (BSA) 
(Sigma–Aldrich) to block nonspecific binding before incubating with the primary 
antibody diluted in 1% BSA-PBS overnight at 4 °C. The samples were rinsed in PBS and 
then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-mouse secondary 
antibody (Dako, Glostrup, Denmark) for 45 min at 37 °C in the dark in a humidified 
chamber. Mounting and nuclei counterstaining were performed using the ‘pro long 
antifade reagent with DAPI’ (Molecular Probes, Invitrogen) and observed under a 
fluorescence microscope (Carl Zeiss Italy, Milano, Italia). 
 
Assessment of RNA polymerase I activity 
Cell nuclei from the six cell lines were extracted in TKM buffer (10 mM Tris-HCl pH 
7.4, 10 mM KCl, 3 mM MgCl2) and suspended in 10 mM Tris-HCl pH 7.4, 0.25 M 
sucrose and 1 mM MgCl2. RNA polymerase I activity was assayed at high ionic strength 
in the presence of α-amanitin ( Derenzini et al. 2005). Five million nuclei of each cell line 
were incubated for 10 min at 37°C in a solution containing: 50 mM Tris-HCl pH 8, 0.2 
mM MnCl2, 140 mM (NH4)2SO4, 0.9 mM ATP, GTP, CTP, 18 mM unlabeled UTP, 
0.05 mM 3[H]UTP, 1 μg/ml α-amanitin. Then two volumes of trichloroacetic acid 5% 
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were added and the radioactivity of the precipitated fraction measured. Results were 
expressed in dpm/μg DNA.  The measurements relative to each cell line were carried out 
in triplicate.  
  
RNA extraction, reverse transcription and Real-Time RT-PCR 
Cells were harvested and total RNA extracted with TRI Reagent solution (Ambion, 
Austin, TX, USA) according to manufacturer’s instructions. Briefly, the cells were 
collected in TRI Reagent solution and incubated at room temperature (RT). After 
centrifugation, the pellet was incubated with chloroform at RT and centrifuged in order to 
obtain the separation of the aqueous phase containing the RNA. This phase was 
transferred in a new tube and the RNA was precipitated by incubation with isopropyl 
alcohol and centrifugation. The RNA pellet was washed in 75% alcohol, air-dried and 
dissolved in DEPC water. Whole cell RNA was quantified with a Nanodrop 
spectrophotometer (ND1000) and 2μg of RNA for each sample were reverse transcribed 
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA) following the manufacturer’s protocol. The relative RNA amounts of 
45S, RPL11, p21, BAX, PUMA, β-glucuronidase, TP53 and c-MYC were evaluated by 
Real-Time RT-PCR performed on an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). β-glucuronidase mRNAs were quantified 
with TaQMan Gene Expression Assays primers and probe kits (Applied Biosystems); 
primers for SYBR Green Real-Time RT-PCR analysis of human 45S rRNA, RPL11, 
BAX, PUMA, p21, TP53 and c-MYC  were designed using the Roche online primers 
design tool.   
For each sample, three replicates were analyzed. Cycling conditions were as follows: 
50°C for 2 min, 95°C for 10 min, 45 cycles at 95°C for 15 s, and 60°C for 1 min.  
33 
 
The relative amount of each RNA sample was analyzed following  the ΔΔCT method: the 
mean ΔCT value of the control sample was used in each experiment to calculate the 
ΔΔCT value of samples replicates (Livak and Schmittgen 2001).  
 
Protein extraction and Western blotting 
Western blotting was performed on whole cell protein extracts and on nuclear protein 
fractions.   
Total cellular proteins were extracted in lysis buffer (KH2PO4 0.1M pH 7.5, NP-40 1%, 
0.1 mM β-glycerolphosphate) supplemented with Complete protease inhibitors cocktail 
(Roche Diagnostics) and quantified spectrophotometrically with the Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Hempstead, UK). Nuclear protein fractions for Western 
blot analysis were obtained accordingly to the method described in Abmayr et al. 2006 
with slight modifications. Samples were mixed with Leammli loading buffer (10% 
Glycerol, 0.2% SDS, 1.5 mM Tris, 0.1% Bromophenol Blue, 1.5 M β-mercaptoethanol) 
and denatured at 95°C for 5 min. 
Denatured protein samples were separated in SDS polyacrylamide gels and transferred to 
nitrocellulose membranes (GE-Healthcare). Aspecific binding sites on the membranes 
were blocked by incubation with 5% non-fat dry milk dissolved in TBS-T solution (20 
mM Tris, 137 mM NaCl, 0.1% Tween 20, pH 7,4). Membranes were blotted overnight at 
4 °C with primary antibody suspended in 3,5% BSA. After the incubation the membranes 
were washed in TBS-T to remove unbound antibody and incubated for 1 h with the 
secondary antibody diluted in 5% milk TBS-T at RT. 
The horseradish peroxidase activity was detected using the appropriate enhanced 
chemiluminescence substrate (Cyanagen) on Hyperfilm enhanced chemiluminescence 
films (Amersham). Densitometric analysis was perfomed using the GelPro analyzer 3.0 
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software (Media Cybernetics). Values from whole protein extraction were normalized on 
corresponding β-Actin expression whereas for nuclear proteins normalization was utilized 
Lamin B expression.  
Primary antibodies utilized in this work are as follow: anti-p53 (clone BP53-12, 
Novocastra Laboratories, Newcastle Upon Tyne, UK), anti-β-actin (clone AC-74, Sigma-
Aldrich), anti-RPL11 (clone 3A4A7, Invitrogen, Carlsbad, UK), anti-PARP-1 (Cell 
Signaling Technology, Beverly, MA, USA), anti-Lamin B (C-20, Santa Cruz 
Biotechnology, CA,USA) anti-MDM2 (clone SMP14 sc-965 and clone H-221, sc-7918, 
Santa Cruz Biotechnology), anti-p21 (clone SXM30, 556431, BD Pharmingen, Milan, 
Italy) and anti-c-MYC (9402, Cell Signaling Technology). Horseradish peroxidase-
conjugated secondary antibodies were from GE-Healthcare (Milano, Italy). 
 
RNAi and transfection reagents 
Select stealth RNAi (Invitrogen) targeted against RPL11 and c-MYC were used, whereas 
a Stealth RNAi negative control was used to transfect controls. Cells were transfected 
with lipofectamine RNAiMAX (Invitrogen) in Opti-MEM medium (Invitrogen), 
accordingly to manufacturer’s procedures.  
 
Co-immunoprecipitation 
Cells were lysed in Co-IP buffer containing 50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 
0.8% NP40, 1 mM dithiothreitol, 1 mM EDTA supplemented with Complete protease 
inhibitor cocktail (Roche Diagnostics). Whole extracts were quantified using Bradford 
assay (Bio-Rad). For each sample 1.5 mg of proteins were incubated overnight at 4°C 
with anti-MDM2 rabbit polyclonal antibody (clone H-221, sc-7918, Santa Cruz 
Biotechnology). The immunocomplexes were then precipitated with Protein A/G PLUS 
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Agarose beads for 4 h at 4 °C. The beads were then centrifuged, washed in Co-IP buffer 
and suspended in Laemmli buffer for subsequent immunoblot analysis, as described in 
“Protein extraction and Western blotting” section. 
 
 
Flow cytometry 
Asynchronously growing HCT116 and HepG2 cells were cultured in standard and serum 
starved media and treated with ActD at a final dose of 8 nM. To evaluate cell cycle 
distribution, cells were harvested and then fixed overnight with EtOH 70% solution at       
-20°C. Cells were incubated with Propidium iodide/RNase staining buffer (BD 
Biosciences Pharmingen, San Jose, California, USA) and analyzed with FACS (Facs 
CantoII, BD Biosciences Pharmingen). Results were analyzed with use of ModFit LT 
software. 
Apoptosis was determined by Annexin V–FITC and propidium iodide double staining 
according to the manufacturer's instructions (Roche Applied Science, Basel, Switzerland). 
Data were collected on a FACS flow cytometer (Facs CantoII, BD Biosciences 
Pharmingen). 
 
 
Clonogenic assay 
HCT116 cells were seeded in normal medium. After c-MYC siRNA interference for 48h, 
the cells were collected and re-seeded in triplicate at the concentration of 1000 cells/well 
then treated with ActD for 24 h. The drug was removed and the cells were grown for 14 
days in normal media. At the end of the period the cells were fixed in methanol and 
stained with 0.5% crystal violet in 25% methanol for 20 min. Finally, the colonies were 
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counted. Results are presented as average of the number of colonies counted in each well 
for each condition. 
 
Statistical analysis 
Correlations between parameters that are considered to be continuous variables were 
analyzed using the Spearman rank correlation test. Differences between groups were 
evaluated by Student’s t–test and p values < 0.05 were considered statistically significant.  
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RESULTS 
 
 
The level of p53 stabilization after the treatment with ribosome biogenesis inhibitors 
is directly proportional to the amount of rRNA synthesis of the cell. 
 
In order to evaluate the effect of rRNA synthesis inhibition on p53 stabilization we 
considered six human tumor cell lines HCT116, HepG2, U2OS, MCF7, LoVo and ZR-
75-1 characterized by different levels of ribosome biogenesis. We evaluated the amount 
of this process both by measuring the radioactivity incorporated in the cells after 
incubation with 
3
H-UTP and by the immunocytochemical analysis of 5-Fluorouridine 
labeling. The results, showed in fig.1 and 2, allowed us to divide the cell lines into two 
groups: one characterized by high levels of rDNA transcription (HCT116, HepG2 and 
U2OS) and one characterized by low rDNA transcription levels (MCF7, LoVo and Zr-
751).  
 
 
 
 
 
 
 
 
Figure 7: Visualization of rRNA synthesis. Cells were labeled with 5-fluorouridine 
for 20 minutes and the fluorescence was revealed by specific FITCH-conjugated 
monoclonal antibody. DAPI counter-staining. The labeling is higher in HCT116, 
HepG2 and U2OS cells than in MCF7, LoVo and ZR-75-1 cells. Scale bar: 10 μm.  
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We treated all the six cell lines for 12 hours with ActD at the concentration of 8 nM, 
which was proved to selectively inhibit the process of rDNA transcription (Perry and 
Kelley 1970). The ActD effect on rRNA synthesis inhibition was evaluated by 
quantitative Real-Time RT-PCR of the 45S rRNA precursor: the drug induced a strong 
inhibition of 45S rRNA synthesis, higher than 75% in all the six lines. We performed 
western blot analysis to evaluate the consequences of rRNA inhibition on p53 
stabilization level in all the cell lines. The level of p53 stabilization was significantly 
higher in HCT116, HepG2 and U2OS than in the MCF7, LoVo and Zr-75-1 and it was 
linearly correlated with the rRNA synthesis of the untreated cells (r = 0.933; P = 0.006). 
These results suggested that the level of p53 stabilization after the inhibition of rDNA 
transcription might depend on the rate of ribosome biogenesis of the cells. 
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Figure 8: Characterization of rRNA transcription level.  rRNA synthesis was 
measured in HCT116, HepG2, U2OS, MCF7, LoVo and ZR-75-1 cell lines by the 
evaluation of [3H]-uridine radioactivity incorporated in the total RNA fraction (DPM/μg 
DNA). 
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To confirm these data and to exclude that genetic differences among the cell lines could 
have influenced the results we selected HCT116 and HepG2, the two lines with the higher 
levels of ribosome biogenesis, and we downregulated the synthesis of rRNA within the 
same cell line by growing them in serum deprived media (Donati et al. 2011). 
The cells grew in normal and serum free media for 24 hours before being treated with 
8nM ActD for 12 hours. The level of rDNA transcription was significantly decreased in 
both cell lines after serum starvation, as assessed by Real-Time PCR analysis of 45S 
rRNA. The treatment with ActD induced a stabilization of p53 which was higher in the 
cells grew in normal media than in serum starved ones; in fact the cells in normal media 
were characterized by higher levels of ribosome biogenesis than the cells in serum free 
media.  
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Figure 9: The level of p53 stabilization induced by ActD is directly related to the cell 
rRNA transcription rate.  a) Real-time PCR analysis of 45S rRNA expression in cells 
treated with 8nM ActD for 12 h. The reduction of 45S rRNA after ActD exposure is similar 
in all cell lines. b) Representative Western blot and densitometric analysis of p53 
expression in control and ActD treated cells. The level of p53 stabilization after ActD 
treatment is higher in HCT116, HepG2 and U2OS cells than in MCF7, LoVo and ZR-75-1 
cells. Histograms show the values (mean ± s.d.) of three experiments.  
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Figure 10: Down-regulation of rRNA synthesis by serum starvation reduces p53 
stabilization after ActD treatment. a) Real time RT-PCR analysis of 45S rRNA expression 
in serum starved and control HCT116 and HepG2 cells. The cells were cultured at low 
serum concentration for 24h and then exposed to 8nM ActD for 12h. The 45S rRNA 
expression is lower in serum starved cells compared with control cells. ActD exposure 
causes a similar reduction of 45S rRNA synthesis. b) and c) Western blot and densitometric 
analysis of p53 expression in serum starved and control HCT116 and HepG2 cells treated 
with 8nM ActD for 12h. The level of p53 stabilization is significantly higher in control than 
in serum starved cells. Histograms show the values (mean ± s.d.) of three experiments. * p < 
0,05; ** p< 0,01; *** p < 0,001. 
b 
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We analyzed by Real Time RT-PCR the levels of TP53 mRNA, both in the six cell lines 
and in the HCT116 and HepG2 with or without serum in the media, to exclude the 
possibility that these results were influenced by different levels of transcription of the 
gene that could slow down the protein translation process.  
The results showed that in the six cell lines the levels of TP53 transcription were not 
correlated to the levels of protein stabilization after ActD treatment and that the serum 
starvation did not influence the levels of TP53 mRNA expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: TP53 rRNA expression is not correlated to the level of p53 protein 
stabilization after ActD exposure. a) Real time RT-PCR analysis of TP53 mRNA 
expression in a) the six cell lines and b) the serum starved and control HCT116 and 
HepG2 cells. The cells were cultured at low serum concentration for 24h.  
Histograms show the values (mean ± s.d.) of three experiments. 
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We also evaluated the effects on p53 stabilization of three other drugs which hinders 
ribosome biogenesis: Doxorubicin (Doxo), 5-fluorouracil  (5-FU)  and CX-5461 (Burger 
et al. 2010; Bywater et al. 2012). We treated the cell lines HCT116, HepG2, MCF7 and 
LoVo with the tree drugs separately, at a dose able to inhibit ribosome biogenesis, and we 
observed in any case greater p53 stabilization in HCT116 and HepG2, which are 
characterized by high levels of ribosome biogenesis, then in MCF7 and LoVo. 
 
 
 
 
 
 
Figure 12 : the level of p53 stabilization induced by Doxorubicin, 5-Fluorouracyl 
and CX-5461 is directly related to the cell rRNA transcription rate.  Western blot 
evaluation and densitometric analysis of p53 expression in HCT116, HepG2, MCF7 and 
LoVo cells treated with a) 10 μM Doxo for 12 h, b) 20μg/ml 5-FU for 12 h and c) 1μM 
CX-5461 for 12 h.  Histograms show the values (mean ± s.d.) of three experiments. 
 
43 
 
To further investigate the relationship between ribosome biogenesis and p53 
stabilization after rRNA synthesis inhibition, we isolated human peripheral blood 
lymphocytes form healthy donors and we incubated them with 10 μM PHA for 72 
hours. The incubation with PHA increased the lymphocytes rDNA transcription rate 
as shown in fig. 12a.  The treatment with 8 nM ActD for 12 hours caused the 
stabilization of p53 in a higher extent in the PHA stimulated lymphocytes compared 
with the control cells.  
 
 
 
 
 
 
 
 
 
 
Figure 13: p53 stabilization after ActD treatment is higher in PHA stimulated 
lymphocytes. a) Real time RT-PCR analysis of 45S rRNA expression in control and 
PHA stimulated lymphocytes. The cells were cultured with 10 μM PHA for 72h and 
then exposed to 8nM ActD for 12h. The 45S rRNA expression increases after PHA 
stimulation and decreases after ActD treatment in both experimental conditions.  
b) Western Blot evaluation of p53 expression in control and PHA stimulated 
lymphocites treated with 8nM ActD for 12 h. The level of p53 stabilization is higher in 
PHA stimulated lymphocytes than in control cells. Histograms show the values (mean 
± s.d.) of three experiments. * p < 0,05; ** p< 0,01; *** p < 0,001. 
b b 
a 
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The level of p53 stabilization after treatment with drugs that do not inhibit ribosome 
biogenesis is independent from the amount of rRNA synthesis of the cell. 
 
To further confirm the results obtained until now, we investigated whether the level 
of p53 stabilization induced by treatments with drugs that do not inhibit rRNA 
synthesis was independent or not from the ribosome biogenesis transcription rate 
of the cell. 
Therefore we utilized two drugs which stabilize p53 without interfering with 
ribosome biogenesis: Hydroxyurea and Nutlin-3. HU inhibits the enzyme 
ribonucleotide reductase and decreases the production of deoxyribonucleotides, this 
causes the activation of ATM that phosphorylates p53 preventing its association 
with MDM2 (Ho et al. 2006). Nutlin-3 causes p53 accumulation by inhibiting 
selectively Mdm-2 (Vassilev et al. 2004).  
We treated four cell lines characterized by different ribosome biogenesis rate, 
HCT116, HepG2, MCF7 and LoVo, with 3, 4 mM HU for 12 hours. The stabilization of 
p53 after the treatment was quite similar in the four cell lines and it was not 
proportional to the ribosome biogenesis levels. The same result was obtained after 
treating with HU the cells HCT116 and HepG2 grown in media with or without 
serum. 
To exclude the possibility that the differences in p53 stabilization were caused by 
differences in Mdm2 amount in the cells, which after the treatment with rRNA 
synthesis inhibitors released different amounts of p53 protein, we treated HCT116 
and HepG2 control and serum starved cells with 10 μM Nut for 12 hours. Also in this 
case, we found that p53 stabilization was independent from the ribosome biogenesis 
rate of the cell.  
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These results showed that p53 stabilization is proportional to the ribosome 
biogenesis level only when induced by treatments that inhibit rRNA synthesis or 
processing, but not when the drugs utilized act through a pathway different from the 
RP-MDM2-p53 one. 
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Figure 14: The level of p53 stabilization induced by drugs that do not act on ribosome 
biogenesis is not related to the cell rDNA transcription rate. a) Western blot evaluation and 
densitormetric analysis of p53 expression in HCT116, HepG2, MCF7 and LoVo cells after 3,4 mM 
HU treatment for 12 h.  The amount of p53 stabilization is quite similar in all cell lines. b) Western 
blot and densitometric analysis of p53 expression in serum starved and control HCT116 and HepG2 
cells treated with 3.4 mM HU for 12h. The amount of p53 stabilization is similar in serum starved 
and control cells. c) Representative Western Blot evaluation of p53 protein expression in serum 
starved and control HCT116 and HepG2 cells treated with 10 μM Nutlin-3 for 12 h. The level of 
p53 stabilization is higher in the serum starved cells than in the controls. Histograms show the 
values (mean ± s.d.) of three experiments. * p < 0,05; ** p< 0,01; *** p < 0,001. 
46 
 
The differences in p53 stabilization level after treatment with ribosome biogenesis 
inhibitors are caused by a different amount of RPs bound to MDM2. 
 
It is known that the rRNA synthesis inhibition can induce the release of ribosomal 
proteins that, no longer utilized for ribosome building, are free to bind to MDM2, 
inhibiting its ubiquitin ligase function and causing p53 accumulation in the cell. 
Therefore we investigated whether the differences observed in the stabilization of p53 
after ActD treatment, in cells characterized by different levels of ribosome biogenesis, 
were connected to this pathway. 
We first silenced the ribosomal protein RPL11 gene expression with RNA interference for 
48 hours in HCT116 and LoVo cells and then we treated them with 8 nM ActD for 12 
hours. We evaluated with Real Time RT-PCR the efficiency of RNA interference for 
RPL11 and it resulted higher than 90% in both cell lines. The western blot analysis, 
performed using the nuclear proteins fraction, showed that in the interfered cells the 
expression of RPL11 decreased and the ActD treatment could not induce p53 
stabilization, whereas in the control cells p53 stabilization was higher in HCT116 than in 
LoVo cells. This result confirmed that the p53 stabilization was dependent on the RPs-
MDM2-p53 pathway and suggested that the differences observed in the level of p53 
stabilization could be caused by a major quantity of RPL11 bound to MDM2 in the cells 
with high ribosome biogenesis after rRNA synthesis inhibition.  
In order to demonstrate this mechanism, we performed an immunoprecipitation for 
MDM2 in HCT116 and LoVo cells treated with ActD and we analyzed the levels of 
RPL11 co-precipitated with it (fig. 15 c). We found that the amount of RPL11 bound to 
MDM2 was greater in the HCT116 than in the LoVo cells after ActD exposure. Indeed 
also the amount of p53 unbound to MDM2, thus not precipitated with it, was higher in 
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HCT116. 
These results showed that the differences observed in p53 stabilization after the inhibition 
of rRNA synthesis were caused by different levels of RPL11 which bound MDM2 
inactivating its ubiquitin-ligase activity.  
 
 
  
 
 
 
 
  
 
 
 
 
Figure 15:  The differences in p53 stabilization are caused by different amount of 
RPL11 bound to MDM2.  a) Real Time RT-PCR of RPL11 mRNA expression in 
HCT116 and LoVo cells to evaluate the efficiency of RPL11 silencing. The cells were 
interfered with RPL11 siRNA for 48h. b) Western blot evaluation of p53 expression in 
control and RPL11 silenced HCT116 and LoVo cells treated with 8nM ActD for 12h 
after the end of the silencing procedure. RPL11 mRNA interference abolishes p53 
stabilization after ActD treatment. c) Western blot evaluation of the amount of RPL11 
bound to MDM2 in HCT116 and LoVo cells after treatment with 8 nM ActD for 12 h.  
Input shows that after ActD treatment p53 stabilization is higher in HCT116 than in 
LoVo cells. After immunoprecipitation with anti-MDM2 polyclonal antibody, the 
amount of RPL11 bound to MDM2 (IP:MDM2) is higher in HCT116 than in LoVo cells. 
Also the amount of p53 in the not immunoprecipitated (No IP) fraction is higher in 
HCT116 cells than in LoVo cells. Histograms show the values (mean ± s.d.) of three 
experiments.  
* p < 0,05; ** p< 0,01; *** p < 0,001. 
a b 
c 
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Figure 16:  p53 stabilization activates p21 mRNA transcription and protein expression. 
a) Real-time RT–PCR analysis of p21 mRNA transcription in control and serum starved 
HCT116 and HepG2 cell lines. HCT116 and HepG2 cells were cultured at low serum 
concentration for 24h and treated with 8nM ActD for 12h. p21 mRNA was significantly 
higher in control than in starved cells. Histograms show the values (mean ± s.d.) of three 
experiments. * p < 0,05; ** p< 0,01; *** p < 0,001. b) Representative Western blot of p21 
expression in control and serum-starved HCT116 and HepG2 cell lines. Starved and control 
cells were treated with 8 nM ActD for 12h. The p21 expression after ActD exposure is 
higher in control than in starved cells. 
The block of the cell cycle after rRNA synthesis inhibition is induced independently 
from the level of p53 stabilization. 
 
We wondered whether the differences observed in p53 stabilization levels after ActD 
exposure could cause a different effect in the progression through the cell cycle phases. 
To investigate this effect we measured the transcriptional activation of p21, a p53 target 
gene, using Real Time RT-PCR analysis in control and serum starved HCT116 and 
HepG2, after ActD exposure. The treatment caused an increase in p21 mRNA expression 
significantly higher in control than in serum-starved cells. The expression of p21 protein 
was also evaluated in control and serum-starved HCT116 and HepG2 cells: after ActD 
exposure, the amount of p21 was higher in control than in serum starved cells. 
 
 
 
 
 
 
 
 
 
HCT116                                                                  HepG2                                                                  
a 
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The protein p21 is an inhibitor of CDK-Cyclin complexes and it is of primary importance 
in the transition from phase G1 to S. To investigate whether different levels of p21 could 
cause a different effect on cell cycle progression we performed a flow cytometry analysis. 
Both HCT116 and HepG2 cell lines were grown in normal or serum free media for 24 
hours, then treated with ActD for 12 hours and their distribution through the cell cycle 
phases analyzed. Serum starvation induced in both cell lines a reduction in the number of 
cells in S phase. Anyway after ActD treatment the normally fed as well as the serum 
starved cells accumulated in the G1 phase in a similar manner. This result showed that the 
lower amount of p53 stabilized was sufficient to induce the block of the cell cycle 
progression in G1 phase at the maximum extent; indeed the higher levels of p53 did not 
increase this effect.  
Figure 17: rRNA synthesis inhibition causes cell cycle progression arrest. Representative 
flow cytometry DNA profiles of control and serum starved HCT116 and HepG2 cells after 
8nM ActD treatment for 12 hours. Cells accumulate mainly in G1/S phase. No differences 
were observed in the profile of serum starved and control cells after ActD exposure. 
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The apoptosis after rRNA synthesis inhibition is induced only in cells with high 
ribosome biogenesis rate in which p53 stabilization is elevated. 
 
Once showed that the different levels of p53 stabilized produced the same effect on the 
progression through the cell cycle we wondered whether the effects on the induction of 
apoptosis could be different proportionally to p53 amount in the cell. 
We evaluated the mRNA transcription activation of two p53 target genes connected with 
apoptosis induction: BAX and PUMA. In control and serum starved HCT116 and HepG2, 
the 12 hours treatment with 8 nM ActD caused an increase in BAX and PUMA mRNA 
transcription significantly higher in control than in serum-starved cells.  
To investigate whether the higher transcription of pro-apoptotic genes after rRNA 
synthesis inhibition could influence the amount of apoptosis we analyzed the cleavage of 
the protein poly (ADP-ribose) polymerase 1 (PARP-1) in normal fed and serum starved 
HCT116 after 12 hours of 8 nM ActD exposure. PARP-1 is an early marker of 
chemotherapy induced apoptosis that is cleaved by activated caspases (Kaufmann et al. 
1993). Only normal fed cells showed PARP-1 cleavage after ActD treatment. This result 
was confirmed by flow cytometry analysis of Annexin V positive cells; Annexin V binds 
to the  phosphatidylserine (PS) expressed on the cell surface during apoptosis (Koopman 
et al. 1994). Only the control cells showed an increase in Annexin V positivity after ActD 
treatment. 
To evaluate the dependence of apoptosis induction on p53 stabilization we 
considered HCT116 p53 null cells (p53 -/-) and we treated them with 8 nM ActD for 
12 hours. The treatment did not induce any PARP-1 cleavage in the p53-/- cells 
whereas the cleavage was observed in wild-type (wt) p53 HCT116.  
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We also examined apoptosis induction after ActD treatment in the six cell lines, 
characterized by different ribosome biogenesis levels through the analysis of PARP-
1 cleavage. The apoptosis was induced only in the cell lines characterized by high 
ribosome biogenesis levels HCT116, HepG2 and U2OS in which ActD treatment 
caused the greatest amounts of p53 stabilized. 
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Figure 18: rRNA synthesis inhibition induces apoptosis only in the cells with high 
ribosome biogenesis rate. a) and b) Real time RT–PCR analysis of the mRNA expression 
of BAX and PUMA in control and serum starved HCT116 and HepG2 cell lines treated 
with 8 nM ActD for 12 h. BAX and PUMA mRNA was significantly higher in control than 
in starved cells. c) Western blot of PARP-1 cleavage in HCT116 serum starved and 
control cells treated with ActD. Cleaved PARP-1 is present only in control treated cells.  
d) Western blot evaluation of PARP-1 cleavage in HCT116 p53 wt and p53-/- cells treated 
with 8 nM Act for 12 h. No cleavage of PARP-1 occurred in p53-/- cells after ActD 
exposure.  e) Flow cytometry DNA analysis for apoptosis detection using Annexin V–
FITCH/propidium iodide double staining. Serum-starved and control HCT116 were 
treated with 8 nM ActD for 24 h. Percentages of cells showing apoptosis (right quadrants) 
are shown in the boxes. f) Western blot of cleaved PARP-1expression in control and ActD 
treated HCT116, HepG2, U2OS, MCF7, LoVo and ZR-75-1. After 8 nM ActD treatment 
for 12 h, cleaved PARP -1 increases in HCT116, HepG2, U2OS cells but not in MCF7, 
LoVo and Zr-75-1. Histograms show the values (mean ± s.d.) of three experiments. * p < 
0,05; ** p< 0,01; *** p < 0,001. 
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Drugs which do not inhibit ribosome biogenesis cooperate with rRNA synthesis 
inhibitors in the stabilization of p53. 
 
Taking into consideration the different mechanism of action by which HU and ActD act, 
we decided to evaluate whether the combination of the two drugs could induce greater 
p53 stabilization compared with that obtained after the single drug treatment. 
We exposed the four cell lines HCT116, HepG2, Mcf7 and LoVo to 3,4 mM HU and 8 
nM ActD, alone or combined, for 12 hours. The combined treatment caused an increase 
in p53 stabilization compared to the single drug treatments only in the Mcf7 and LoVo 
cell lines, the ones characterized by low levels of ribosome biogenesis. In parallel we 
analyzed PARP-1 cleavage, after the singles or the double treatments, and we found that 
only in the Mcf7 and LoVo cells the combination of the two drugs increased the protein 
cleavage. On the contrary, in the HCT116 and HepG2 cells no increase in p53 
stabilization and PARP-1 cleavage was observed after the combined treatment compared 
with the single treatments.  
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Accordingly with these results, the combination of rRNA synthesis inhibitors with drugs 
which do not inhibit ribosome biogenesis, such as HU, increased the effectiveness of the 
treatment only in the cells characterized by low ribosome biogenesis rate.  
 
 
 
Figure 19: Drugs not acting on ribosome biogenesis may cooperate with inhibitors of 
rRNA synthesis in p53 stabilization. a) Representative western blot and densitometric 
analysis of p53 expression and PARP-1 cleavage in MCF7 and LoVo cells. Cells were 
treated with either 8nM ActD or 3.4 mM HU, separately or together for 12h. The 
contemporary treatment with HU and ActD causes a major p53 stabilization compared to 
single drugs exposure and induces an increase in PARP-1 cleavage in both cell lines.  
b) Western blot and densitometric analysis of p53 expression and PARP-1 cleavage in 
HCT116 and HepG2 cells. Cells were treated with 8nM ActD and/or 3.4 mM HU for 12h. 
The contemporary treatment with HU and ActD does not increase the amount of p53 
stabilization and PARP-1 cleavage in both cell lines, in comparison with that obtained after 
the exposure to ActD alone.  
Histograms show the values (mean ± s.d.) of three experiments.  
b 
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rRNA synthesis inhibition causes apoptosis in the cells with MYC overexpression 
 
The research proceeded evaluating the relationship among MYC expression, the ribosome 
biogenesis level of the cell and the cytotoxic effects caused by p53 stabilization after 
rRNA synthesis inhibition. In fact, as previously explained in the introduction, the protein 
MYC has a stimulatory effect on ribosome biogenesis. 
At first, we evaluated MYC protein expression in the six cell lines HCT116, HepG2, 
MCF7, U2OS, LoVo and Zr-75-1, comparing it with the rDNA transcription rate of the 
cells (showed in fig. 7). The result showed that the level of MYC expression was directly 
proportional to the ribosome biogenesis rate of the cells.  
Moreover we transiently interfered c-MYC in the HCT116 cell line and we observed a 
decrease in both c-MYC mRNA and protein and a significant reduction of the rRNA 
synthesis level of the cells.  
These results showed that MYC overexpression could be responsible for the differences 
in the levels of ribosome biogenesis among the different cell lines.  
Next step was to investigate the effects of rRNA synthesis inhibition in cells 
characterized by different levels of MYC expression. After having reduced MYC 
expression by a 48 hours interference with siRNA in HCT116, which normally have high 
levels of MYC expression, we treated the cells with 8 nM ActD for 8 and 24 hours. The 
treatment induced a p53 stabilization which was greater in the not interfered cells, 
characterized by higher levels of ribosome biogenesis, then in the interfered cells where 
both MYC expression and ribosome biogenesis were reduced. We also showed that the 
treatment with rRNA synthesis inhibitors induced the apoptosis in the control cells but 
not in the c-MYC interfered cells. We analyzed the cleavage of PARP-1 after ActD 
exposure: it was higher in the control cell than in the c-MYC interfered cells. 
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Moreover we performed a clonogenic assay to confirm this result. We observed that 15 
days after the treatment with 8 nM ActD for 24 hours the formation of colonies was 
greater in the c-MYC interfered cells than in the controls, probably because the drug 
induced the apoptotic death of a major number of cells in the control not-interfered cells 
than in the c-MYC silenced cells.  
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Figure 20: rRNA synthesis inhibition induces apoptosis in the cells with MYC 
overexpression.  a) MYC expression is greater in HCT116, HepG2 and U2OS than in 
MCF7, LoVo and ZR-75-1 cells. b) Real-time RT-PCR and Western blot evaluation of c-
MYC expression in HCT116 cells after 48h interference. c) Real time RT-PCR evaluation 
of 45S rRNA expression in control (Scr) and c-MYC silenced (MYC-) HCT116 cells 
treated with 8 nM ActD for 8 and 24h. The 45S rRNA is lower in interfered cells 
compared with control cells.  d) Western blot and densitometric analysis of p53 
expression in control and MYC- HCT116 cells. After ActD treatment the level of p53 
stabilization is higher in control (Scr) than in MYC- cells. e) Western blot and 
densitometric analysis of cleaved PARP-1 in control (Scr) and MYC- HCT116 cells. 
After ActD treatment the expression of the cleaved PARP-1 is higher in control than in 
MYC- cells. f) Clonogenic assay performed with control (Scr) and MYC- HCT116 cells, 
treated with 8 nM ActD for 24h. After 15 days from ActD exposure the reduction of the 
number of colonies is greater in control than in MYC- HCT116 cells. 
Histograms show the values (mean ± s.d.) of three experiments. * p < 0,05; ** p< 0,01; 
*** p < 0,001. 
 
These data showed that the cells in which MYC was overexpressed were characterized by 
high levels of ribosome biogenesis and that the treatment with rRNA synthesis inhibitors 
induced a great p53 stabilization that could cause the cell death by apoptosis. 
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DISCUSSION 
 
Many drugs utilized in cancer chemotherapy inhibit the ribosome biogenesis process 
evoking a p53 response, in p53 wild-type tumors, and the level of p53 stabilization may 
be important for the efficacy of the anticancer treatment. For this reason we studied the 
degree of p53 stabilization after treatments with rRNA synthesis inhibitors in relation 
with the cell ribosomal biogenesis rate, in cancer cell lines with functional p53. We 
showed that a direct relationship exists between the amount of p53 stabilized after rRNA 
synthesis inhibition and the ribosome biogenesis level of the cancer cells before the 
treatment.  
We used several drugs which interfere with rRNA synthesis or processing: ActD, Doxo, 
5-FU and CX-5461. ActD is an anticancer antibiotic which at low doses preferentially 
intercalates into the GC rich regions of rDNA inhibiting Pol I mediated transcription of 
nascent 47S rRNA (Perry and Kelley 1970). Doxorubicin is another anticancer antibiotic 
which intercalates in the DNA causing rRNA synthesis inhibition, but with less 
specificity for rDNA than ActD (Burger et al. 2010). 5-FU is a potent inhibitor of rRNA 
metabolism, indeed it was found to form stable adducts with dyskerin pseudouridine 
synthase. It  confers cytotoxicity by the reduction of pseudouridylation of rRNA, which is 
a requirement for correct rRNA processing (Hoskins and Butler 2008). CX-5461 
specifically blocks the recruitment of the SL1 complex which is essential for Pol I 
initiation and inhibits rRNA synthesis (Bywater et al. 2012).  
When we treated with these drugs different cancer cell lines characterized by different 
levels of ribosome biogenesis we found that the amount of stabilized p53 was 
significantly greater in cells characterized by high ribosome biogenesis levels than in 
those with low rDNA transcription rate. The same result was obtained comparing cells 
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with high ribosome biogenesis rate with the same type of cells in which ribosome 
biogenesis rate was downregulated by serum starvation. In fact ActD treatment induced 
lower p53 stabilization in serum-starved cells compared with the normal feed ones.  
This was not the case if drugs which do not interfere with rRNA synthesis, such as HU 
and Nutlin-3, were used. These drugs caused quite similar p53 stabilization levels in cell 
lines characterized by different ribosome biogenesis rate. 
 
We demonstrated that the different levels of p53 stabilization induced by rRNA synthesis 
inhibitors in cells with high and low ribosome biogenesis rate were the consequence of 
the fact that different amounts of RPs, not anymore used in ribosome assembling,  bind to 
the ubiquitin ligase MDM2 and hinder p53 proteosomal degradation. We observed that 
the downregulation of RPL11, one of the main RPs able to inactivate MDM2, deleted the 
differences observed in p53 stabilization between high and low ribosome biogenesis cells 
after ActD treatment. Furthermore, we showed that the amount of RPL11 that bind to 
MDM2, as a consequence of rRNA synthesis inhibition, was greater in cells with high 
ribosome biogenesis rate than in those with low ribosome biogenesis. In fact in the cells 
characterized by high rDNA transcription levels also a high production of RPs occurs and 
the inhibition of rRNA synthesis causes a large number of RPs, no longer used for 
ribosome building, to bind and neutralize a large number of MDM2 molecules, thus 
inducing high p53 stabilization. Whereas, the inhibition of ribosome biogenesis in the 
cells with low rDNA transcription levels induces few RPs to bind to MDM2, thus only 
partially neutralizing the ubiquitin ligase activity toward p53, with a consequent low- 
level p53 stabilization.  
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The following step of the present study was to assess the relationship between different 
amount of p53 stabilization after inhibition of rRNA synthesis and the degree of the 
induced cytotoxic effects. In the nucleus p53 works predominantly as a transcription 
factor that enhances the rate of transcription of several genes connected with cell 
proliferation and apoptosis (Ryan et al. 2001). We demonstrated that the mRNA 
transcription activation of the p53 target genes p21, BAX and PUMA was proportional to 
the level of p53 stabilization after rRNA synthesis inhibition.  
 Concerning the cytostatic effect, the protein p21 is a CDK inhibitor of primary 
importance in G1 regulation (Polyak et al. 1994). We observed that after rRNA synthesis 
inhibition the block of cell cycle progression occurred independent of the amount of p53 
stabilization, with cells accumulation mainly in G1 phase.  
Then, we investigated the effects on apoptotic cell death induction of different levels of 
p53 stabilization. We found that in cell lines with a high ribosome biogenesis rate the 
inhibition of rRNA synthesis resulted not only in the cell cycle arrest, but also in 
apoptotic cell death. In cell lines with low level of ribosome biogenesis the inhibition of 
rRNA synthesis did not cause apoptotic cell death. These different effects were dependent 
on p53 stabilization. In fact, when we treated HCT116 p53 null cells with ActD we did 
not observed the induction of apoptosis, at differences of p53 wild-type HCT116 cells. 
Altogether, these results indicate that after the treatment with rRNA synthesis inhibitors 
the activation of apoptosis is dependent on the level of p53 in the cell. This result is 
consistent with previous data described in literature (Lai et al. 2007). 
These results might explain the findings by Bywater and colleagues; they studied the 
effects of the rRNA synthesis inhibitor CX-5461 in a mouse model of lymphoma with 
MYC overexpression (Eμ-Myc). This drug was able to induce a p53-mediated apoptotic 
cell death selectively in transformed malignant cells, sparing normal B cells. MYC in fact 
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is a powerful activator of ribosome biogenesis and for this reason we hypothesized that its 
overexpression could make the malignant cells more susceptible to treatments with rRNA 
synthesis inhibitors. In our study we demonstrated that the cancer cells characterized by 
MYC overexpression died by apoptosis after the treatment with rRNA synthesis 
inhibitors. Analyzing the expression of MYC protein we found a correlation with the 
levels of ribosome biogenesis of the cells. Moreover the c-MYC gene silencing decreased 
the rRNA synthesis rate in HCT116 cells and after ActD treatment the level of p53 
stabilization and apoptosis was lower than in the normal cells.  
 
In this study we also showed the importance of associating drugs which stabilize p53 by 
inhibiting rRNA synthesis to drugs which induce p53 stabilization through different 
pathways in cells characterized by low ribosome biogenesis rate.  
We observed that the association of ActD with HU induced a p53 stabilization in the 
MCF7 and LoVo cells that was higher than that obtained with the single drug treatments, 
and induced the apoptotic cell death.  
We did not observe this additive effect in the cell lines (HCT116 and HepG2) with high 
ribosome biogenesis rate, in which the maximum amount of p53 stabilization and 
apoptosis was obtained after the single ActD treatment and the combination with HU did 
not increase p53 stabilization. This can be explained by the fact that in cells with high 
ribosome biogenesis rates, the inhibition of rDNA transcription makes large amounts of 
RPs free to bind to MDM2 and, very likely, to neutralize its ubiquitin-ligase activity 
completely, with the consequent stabilization of all the synthesized p53. Therefore, the 
phosphorylation of p53 caused by HU cannot modify the final amount of stabilized p53. 
On the other hand, if the cells are characterized by a low ribosome biogenesis rate, the 
inhibition of the synthesis of rRNA makes small amounts of RPs free to bind to MDM2, 
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with a partial neutralization of its ubiquitin-ligase activity and the consequent 
stabilization of only a portion of p53. In this case HU exposure may increase the total 
amount of stabilized p53 by phosphorylating p53 thus hindering its binding to the still 
active portion of MDM2.  
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
The results presented in this study allow us to conclude that, in case of wild-type p53 
cancers, those with high levels of ribosomal biogenesis could strongly benefit from 
treatments with drugs that inhibit rRNA synthesis. In fact, in these cancers the drug 
treatment promotes a high activation of p53 with the consequent induction of apoptotic 
death. Conversely, the treatment with rRNA synthesis inhibitors of tumors characterized 
by low ribosomal biogenesis rate induces a low p53 stabilization level that does not 
induce cancer cells death, but only the arrest of the cell cycle progression. For this reason 
the inhibitors of the rRNA synthesis alone should be considered in the treatment of 
cancers characterized by high levels of ribosome biogenesis but cannot be recommended 
for the treatment of cancers characterized by low ribosome biogenesis levels. In this type 
of cancers, in order to obtain a p53 stabilization sufficient to activate the apoptotic 
pathway, it might be useful to combine treatments with ribosomal biogenesis inhibitors, 
which stabilize p53 through the RPs-MDM2 pathway, with drugs that stabilize p53 
through a different pathway, e.g. by p53 phosphorylation, in order to increase p53 
stabilization level and to induce apoptotic cell death. 
Altogether, these results suggest that in order to choice an appropriate chemotherapy the 
evaluation of the ribosomal biogenesis rate should be carried out in the neoplastic tissues. 
This evaluation can be easily performed by measuring the size of the nucleolus on 
histological samples which is in fact directly proportional to the ribosomal biogenesis rate 
of the cell (Derenzini et al.  2009). 
These findings, demonstrating the important cytotoxic effects of the inhibition of 
ribosome biogenesis on cancer cells, stimulate more studies aiming to identify 
compounds that selectively target the ribosome biogenesis.  
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In this context, worthy of mention are some recent works in which a small molecular 
compound, BMH-21, and a small-molecule peptide (22mer) have been found to stabilize 
p53 by inhibiting rDNA transcription. The small molecular BMH-compounds inhibit 
nascent rRNA synthesis and cause nucleolar stress by the proteasome dependent 
destabilization of the RPA194 subunit of the Pol I (Peltonen et al. 2014). The small-
molecule peptide (22mer) targets the interface between RNA polymerase I and Rrn3 thus 
selectively inhibiting the synthesis of rRNA (Rothblum et al. 2014). 
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NOTES 
 
The work described in this thesis led to the publication of the following paper: 
Scala F, Brighenti E, Govoni M, Imbrogno E, Fornari F, Treré D, Montanaro L, 
Derenzini M. Direct relationship between the level of p53 stabilization induced by rRNA 
synthesis-inhibiting drugs and the cell ribosome biogenesis rate. Oncogene. 2015 May 11.  
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